Novavax | Up to 76 million | Novavax Nuvaxovid authorization | |
---|---|---|---|
Sanofi and GlaxoSmithKline | Up to 72 million | No |
https://www.canada.ca/en/public-services-procurement/services/procuring-vaccines-covid19.html
https://www.sanofi.com/en/media-room/press-releases/2022/2022-11-10-15-36-50-2553486